Infectious Diseases
Redwood AI Signs LOI for AI-Enabled Pathogen Surveillance Initiative in East Africa
Redwood AI Corp. has signed a non-binding letter of intent to collaborate on a pathogen tracking and outbreak intelligence initiative in Central and East Africa, aiming to enhance early detection of infectious diseases using AI.
VolitionRx Expands Patent Portfolio with Ebola Triage Application
VolitionRx has filed a patent for using its Nu.Q technology to triage and monitor potential Ebola patients, aiming to provide low-cost bedside testing in resource-limited outbreak zones.
GeoVax CEO Sees Renewed Strategic Interest in Vaccine Platforms as Industry Shifts Toward Health Security
GeoVax Labs CEO David Dodd comments on recent pharmaceutical acquisitions, highlighting a strategic shift toward vaccine innovation and health security amid rising global infectious disease threats.
CDC Expands Ebola Travel Ban to U.S. Green Card Holders from Uganda, South Sudan, and DRC
The U.S. CDC has extended its Ebola travel ban to include green card holders who have been in Uganda, South Sudan, or the DRC in the past 21 days, raising concerns among healthcare stakeholders about potential disease importation.
Climate Change Amplifies Infectious Disease Risks, Experts Warn
Experts warn that climate change is increasing the risk of infectious diseases, cancer, and heat stress, prompting a need for expanded diagnostic access to curb outbreaks.
NanoViricides Proposes NV-387 for Bundibugyo Ebola Outbreak Amid Lack of Approved Treatments
NanoViricides highlights its broad-spectrum antiviral NV-387 as a potential treatment for the Bundibugyo Ebola outbreak in Africa, where no approved vaccines or therapies exist, leveraging its host-targeted mechanism and oral formulation for easier deployment.
GeoVax CEO David Dodd to Discuss MVA-Based Vaccine Platforms for Broader Infectious Disease Preparedness in Tribe Public Webinar
GeoVax Labs CEO David Dodd will participate in a Tribe Public webinar on May 28, 2026, to discuss the need for platform-based vaccine technologies to address multiple viral threats like Ebola, Marburg, mpox, and hantavirus, emphasizing the limitations of single-threat preparedness.
GeoVax Highlights MVA Platform's Potential Amid Bundibugyo Ebola Outbreak
GeoVax Labs comments on the WHO-declared PHEIC for Bundibugyo Ebola, emphasizing the need for flexible vaccine platforms like its MVA-based technology to address emerging viral threats.
GeoVax Raises $3 Million in Private Placement to Fund Vaccine Development
GeoVax Labs secures $3 million through a private placement with institutional investors to advance its mpox/smallpox vaccine and other pipeline programs.
NanoViricides Highlights Broad-Spectrum Antiviral NV-387 Amid Ebola Outbreak
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool amid the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda.
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Hantavirus Outbreak on Cruise Ship Raises Concerns Over Little-Known Infection
A hantavirus outbreak on the MV Hondius cruise ship has resulted in three fatalities, highlighting the need for awareness and diagnostic solutions for this rare but deadly virus.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Pipeline
NanoViricides has completed a $6 million capital raise to fund development of its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development
NanoViricides has raised $6 million through a registered direct offering and concurrent private placement, providing crucial capital to advance its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
Viral Infections Significantly Increase Heart Attack and Stroke Risk, Study Finds
New research reveals that both acute infections like influenza and COVID-19 and chronic viral infections including HIV and hepatitis C substantially elevate cardiovascular disease risks, highlighting the importance of preventive measures including vaccination.
New IDSA Guidelines Highlight Critical Need for Tailored COVID-19 Vaccines for Immunocompromised Population
GeoVax's GEO-CM04S1 vaccine addresses the significant protection gap for over 40 million immunocompromised Americans who experience limited effectiveness from current COVID-19 vaccines, as highlighted by new Infectious Diseases Society of America guidelines.
NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus with significant lung protection and extended survival in animal models, potentially offering the first approved treatment for a disease that currently has no specific antiviral therapy.
NanoViricides' Dual-Track Clinical Strategy for NV-387 Antiviral Drug Highlighted in Analyst Report
NanoViricides is advancing its broad-spectrum antiviral drug candidate NV-387 through a dual-track clinical development strategy targeting both MPox and respiratory viral infections, with potential implications for global pandemic preparedness and biodefense funding opportunities.
Nightmare Bacteria Infections Surge in U.S., Prompting Urgent Response from Biotech Sector
The rapid spread of antibiotic-resistant 'nightmare bacteria' in the United States is driving increased focus on biotech companies developing novel treatments to address this growing public health crisis.
NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025
NanoViricides will showcase its clinical-stage nanoviricide technology targeting multiple viral diseases at the LSX World Congress, highlighting its potential to address unmet medical needs through a novel antiviral approach.
Soligenix Announces Two-Year Stability for Thermostable Ebolavirus Vaccines
Soligenix's ThermoVax platform demonstrates extended vaccine stability at elevated temperatures, potentially revolutionizing global distribution and pandemic preparedness for Ebola and related viruses.
Erica Ollmann Saphire Honored with 2025 San Diego Genius Award for Pioneering Immunology Research
Dr. Erica Ollmann Saphire, a leading figure in immunology research, is set to receive the 2025 San Diego Genius Award for her groundbreaking work on viral infections and immune system responses, highlighting the intersection of science and community enrichment.
NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks
NanoViricides Inc. announces its drug candidate NV-387 could significantly impact the treatment of measles, addressing a critical gap in antiviral medications amid rising global outbreaks.
NanoViricides' NV-387 Shows Promise as Broad-Spectrum Antiviral with Strategic Pandemic Preparedness Value
NanoViricides, Inc. highlights NV-387's broad antiviral potential and its strategic importance for pandemic preparedness, with plans for a Phase II trial targeting MPox.
NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study
NanoViricides, Inc. reports a significant breakthrough with its lead drug candidate, NV-387, showing increased survival rates in a lethal measles infection model, highlighting the potential for the first therapeutic option amid rising global measles cases.